They performed in vivo functional validation of this synthetic lethal relationship by inducing CRISPR‐SpCas9‐mediated VPS4A suppression in rhabdomyosarcoma and pancreatic ductal adenocarcinoma PDTXs deficient of VPS4B and showed this resulted in near‐complete tumour regression (Neggers et al, 2020). The gene discussed is VPS4A; the disease is neoplasm.